Cellbyte has raised $2.75 million in seed funding to transform how pharmaceutical companies launch new drugs, just weeks after reaching six-figure ARR. The AI-native platform uses generative AI to streamline pricing, regulatory, and market access workflows for faster, data-driven launches. The round was led by Frontline Ventures with participation from Y Combinator, Pace Ventures, Saras Capital and Springboard Health Angels.
The funding comes as the startup experiences significant early traction. The messy data landscape across the pharmaceutical industry means life saving drugs can take more than a year to reach patients. Market Access teams must produce complex regulatory documentation and craft pricing and reimbursement strategies, often relying on fragmented tools or expensive third party support. Pharmaceutical companies routinely spend hundreds of thousands of dollars just to access essential pricing and market data.
Cellbyte aims to streamline these processes through an AI native platform that allows drug launch teams to analyse millions of data points in real time across clinical, pricing, HTA, regulatory and internal company sources. By delivering fast, reliable and high quality insights, the platform helps teams prepare documents, determine launch sequences and shape go to market strategies on a dramatically reduced timeline.
Legacy databases were built before the LLM era and only surface the most accessible layer of information. They often fail to reach the depth and granularity needed by pricing and market access teams. Cellbyte’s platform goes further by providing a comprehensive, up to date and interconnected data foundation that supports high stakes workflows. Processes that once took as long as a year can now be completed in minutes without compromising quality.
Co-CEO and Co-Founder Felix Steinbrenner said the industry is overdue for a shift.
“The success of a drug’s entire lifecycle is decided in its launch sequence. Insights derived from gigabytes of accurate, up to date information are needed to make the best decisions for a launch. The traction Cellbyte has secured with some of the world’s biggest pharmaceutical companies since its launch shows the industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost effective processes.”
Co-CEO and Co-Founder Daniel Moreira added that generative AI is reshaping a part of the industry that has long lagged behind. “Based on my years in Life Science Consulting, I have seen countless innovations transforming clinical development. Yet in Pricing and Market Access, decisions still too often rely on manual work and anecdotal evidence even though information is so abundant. Now generative AI is changing that, and we are proud to be driving this shift.”
Cellbyte was founded in 2024 by Daniel Moreira, Felix Steinbrenner and Samuel Moreira. The team’s combined expertise in pharmaceutical consulting, AI and machine learning, and startup building positions the company to redefine drug launches. Daniel brings first hand experience dealing with legacy data storage systems that make it difficult to answer critical launch questions. Samuel brings deep technical expertise in building AI applications. Felix brings operator experience as a second time founder and Y Combinator alumnus.
The startup has already scaled to six figures in ARR within weeks of launch and has secured contracts with major pharmaceutical companies including Bayer. It continues to expand its coverage across key global markets.
With the new funding, Cellbyte plans to triple its headcount and expand engineering capabilities to meet rising customer demand. The company aims to become the primary operating system for commercial pharmaceutical teams worldwide.
Frontline Ventures Partner William McQuillan said the team is tackling one of the industry’s most persistent challenges. “Cellbyte is tackling one of pharma’s biggest bottlenecks with an AI driven strategy. Felix, Samuel and Daniel have set their sights globally from day one and we are proud to support them as they expand into the United States and accelerate patient access to new treatments.”
